# A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

> **NCT07243340** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmVira Pharma Co. Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **BIOLOGICAL:** Herpes Virus C5252 Injection

## Key facts

- **NCT ID:** NCT07243340
- **Lead sponsor:** ImmVira Pharma Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2027-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243340, "A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07243340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*